Literature DB >> 21145947

Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.

S Walsh1, D P Finn, E Dowd.   

Abstract

The pathogenesis of Parkinson's disease is thought to involve a self-sustaining cycle of neuroinflammation and neurodegeneration. In order to develop novel anti-inflammatory therapies to break this cycle, it is crucial that the temporal relationship between neurodegeneration and neuroinflammation is characterised in pre-clinical models to maximise their predictive validity. Thus, this study aimed to investigate the progression of neuroinflammation relative to nigrostriatal neurodegeneration in the two most commonly-used rat models of Parkinson's disease. Male Sprague-Dawley rats were lesioned by terminal or axonal administration of 6-hydroxydopamine, and were sacrificed for quantitative immunohistochemistry (to assess nigrostriatal integrity (anti-tyrosine hydroxylase), microgliosis (anti-OX42) and astrocytosis (anti-GFAP)) at 6 h 24 h 72 h or 2 weeks post-lesion. Following terminal lesion, dopaminergic deafferentation of the striatum was evident from 6 h post-lesion and was accompanied by microglial and astroglial activation. Dopamine neuron loss from the substantia nigra did not occur until 2 weeks after terminal lesion, and this was preceded by microglial, but not astroglial, activation. Following axonal lesion, retraction of nigrostriatal terminals from the striatum was not observed until the 72 h time-point, and this was associated with a slight astrocytosis, but not microgliosis. Degeneration of dopaminergic neurons from the substantia nigra was also evident from 72 h after axonal lesion, and was accompanied by nigral microgliosis and astrocytosis by 2 weeks. This study highlights the temporal relationship between neurodegeneration and neuroinflammation in models of Parkinson's disease, and should facilitate use of these models in the development of anti-inflammatory therapies for the human condition. Copyright Â
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145947     DOI: 10.1016/j.neuroscience.2010.12.005

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  37 in total

1.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

2.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

Review 3.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

4.  Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease.

Authors:  Irving Parra; Isabel Martínez; Gabriel Ramírez-García; Yousef Tizabi; Liliana Mendieta
Journal:  Neurotox Res       Date:  2019-09-02       Impact factor: 3.911

5.  Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.

Authors:  Zahra Kiasalari; Tourandokht Baluchnejadmojarad; Mehrdad Roghani
Journal:  Cell Mol Neurobiol       Date:  2015-06-29       Impact factor: 5.046

6.  Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons.

Authors:  Louise M Collins; Gerard W O'Keeffe; Caitriona M Long-Smith; Sean L Wyatt; Aideen M Sullivan; André Toulouse; Yvonne M Nolan
Journal:  Neuromolecular Med       Date:  2013-04-13       Impact factor: 3.843

7.  ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2015-07-30       Impact factor: 5.590

8.  Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.

Authors:  Andrea Lopez-Lopez; Carmen M Labandeira; Jose L Labandeira-Garcia; Ana Muñoz
Journal:  Br J Pharmacol       Date:  2020-11-03       Impact factor: 8.739

9.  [18F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration.

Authors:  Tatiana Rodríguez-Chinchilla; Ana Quiroga-Varela; Francisco Molinet-Dronda; Arantzazu Belloso-Iguerategui; Leyre Merino-Galan; Haritz Jimenez-Urbieta; Belén Gago; María Cruz Rodriguez-Oroz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-23       Impact factor: 9.236

Review 10.  Innate inflammation in Parkinson's disease.

Authors:  V Hugh Perry
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.